118 patients with progressing glaucoma were randomly assigned to NR (n=61) or placebo (n=57). The baseline (15.6 vs 16.5 mmHg, P=0.185) and week-4 IOP (15.1 vs 15.7 mmHg, P=0.308) was comparable between the groups. At week 4, the VF MD, decreased by 0.29 dB (95% CI:0.08-0.50; P=0.006) in the placebo group; no significant change was detected in the NR group (-0.13 dB, 95% CI:-0.33-0.06, P=0.185). Ten (18.5%) and 3 (5.6%) of the 54 VF locations showed significant decreases in VF sensitivity, respectively. No significant changes of RNFL thickness were detected in the NR group or the placebo group at week 4. Two patients, one in each group, developed gastrointestinal upset. NR averted VF sensitivity worsening in progressing glaucoma although it did not show a neuroenhancement effect.